baxter international inc (BAX*:Mexico)
Transactions by BAXTER INTERNATIONAL INC (BAX*) in the last 6 months
Baxter International Inc. (NYSE:BAX) acquired AesRx, LLC on July 9, 2014. Baxter made an initial payment to acquire AesRx and may make additional future payments based on specified development, regulatory and commercial milestones.
Baxter International Inc. (NYSE:BAX) agreed to acquire membership interests of Chatham Therapeutics, LLC for $70 million on April 2, 2014. As per the terms of the deal, Baxter will make an initial payment of $70 million and may make additional payments in the future based on specified development, regulatory and commercial milestones. Following the acquisition, Chatham will maintain its licensing and development relationship with Asklepios BioPharmaceutical, Inc.
The Board of Baxter International Inc. (NYSE:BAX) announced the spin-off of its biopharmaceuticals assets on March 27, 2014. Baxter International Inc. will form two separate publicly traded companies, one focused on biopharmaceuticals and the other focused on medical products, through a distribution to Baxter stockholders of shares in the new biopharmaceutical company. The biopharmaceuticals business reported revenues of $6 billion for the year ended December 31, 2013. ...
Xenetic Biosciences, Inc. announced that it has received $10 million in equity funding from existing investor Baxter International Inc. on January 30, 2014.
|Astellas Pharma Inc||¥1,402 JPY||+2.00|
|Covidien PLC||$89.10 USD||-0.19|
|Danone SA||€55.99 EUR||+0.01|
|Kimberly-Clark Corp||$109.49 USD||-0.01|
|Takeda Pharmaceutical Co Ltd||¥4,713 JPY||+39.00|
|View Industry Companies|